ロード中...
Dasatinib suppresses atherosclerotic lesions by suppressing cholesterol uptake in a mouse model of hypercholesterolemia
Although the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia is known to cause vascular adverse events (VAEs), the frequency of VAEs during dasatinib administration is not high, and the same holds for atherosclerosis-related VAEs. However, its effect on atherosclerosis...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2022-07-01
|
| シリーズ: | Journal of Pharmacological Sciences |
| 主題: | |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S1347861322000366 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|